Cartesian Therapeutics (RNAC) Other Non-Current Assets (2015 - 2026)

Cartesian Therapeutics (RNAC) has 11 years of Other Non-Current Assets data on file, last reported at $1.7 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $1.7 million, up 1.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 million (up 1.86% YoY), and the FY2025 annual result was $5.6 million, up 971.62% from the prior year.
• Other Non-Current Assets fell to $1.7 million in Q1 2026 per RNAC's latest filing, from $5.6 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $5.6 million in Q4 2025 and troughed at $518000.0 in Q4 2024.
• A 5-year average of $1.7 million and a median of $1.6 million in 2022 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets fell 13.94% in 2023, then jumped 971.62% in 2025.
• A 5-year view of Other Non-Current Assets shows it stood at $1.6 million in 2022, then dropped by 13.94% to $1.4 million in 2023, then slumped by 62.38% to $518000.0 in 2024, then jumped by 971.62% to $5.6 million in 2025, then sank by 69.37% to $1.7 million in 2026.
• Business Quant data shows RNAC's Other Non-Current Assets at $1.7 million in Q1 2026, $5.6 million in Q4 2025, and $1.7 million in Q3 2025.